4Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol, 2009 ;84:215 - 220.
5Cha JK, Jeong MH, Lee KM, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis, 2002 ; 14 : 145 - 150.
6Karakantza M, Maniatis A, Metallinos CI, et al. In vivo platelet activation in ischemic stroke patients. Stroke, 2003 ;34 : e174 - 175.
7Yip HK, Chen SS, Liu JS, et al. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke, 2004; 35:1683- 1687.
8ARELLANO- RODRIGO E, ALVAREZ- LARRAN A, REVERTER JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden [ J ]. Am J Hematol, 2009,84 ( 2 ) : 102-108.
9PALANDRI F,OTTAVIANI E,SALMI F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients [ J ]. Leuk Lymphoma, 2009,50 ( 2 ) : 247- 253.
10VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization ( WHO ) classification of the myeloid neoplasms [ J ]. Blood, 2002,100 ( 7 ) :2292- 2302.
